163 related articles for article (PubMed ID: 29729071)
1. Syntheses and evaluation of
Chakraborty S; Goswami D; Chakravarty R; Mohammed SK; Sarma HD; Dash A
Chem Biol Drug Des; 2018 Sep; 92(3):1618-1626. PubMed ID: 29729071
[TBL] [Abstract][Full Text] [Related]
2. Preparation and evaluation of a radiogallium complex-conjugated bisphosphonate as a bone scintigraphy agent.
Ogawa K; Takai K; Kanbara H; Kiwada T; Kitamura Y; Shiba K; Odani A
Nucl Med Biol; 2011 Jul; 38(5):631-6. PubMed ID: 21718937
[TBL] [Abstract][Full Text] [Related]
3. A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting.
Meckel M; Kubíček V; Hermann P; Miederer M; Rösch F
Nucl Med Biol; 2016 Nov; 43(11):670-678. PubMed ID: 27560354
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, Quality Control, and Bench-to-Bed Translation of a New [
Chakraborty S; Chatterjee S; Chakravarty R; Sarma HD; Nanabala R; Goswami D; Joy A; Pillai MRA
Cancer Biother Radiopharm; 2024 Feb; 39(1):92-101. PubMed ID: 38335449
[No Abstract] [Full Text] [Related]
5. Development of [(90)Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases.
Ogawa K; Kawashima H; Shiba K; Washiyama K; Yoshimoto M; Kiyono Y; Ueda M; Mori H; Saji H
Nucl Med Biol; 2009 Feb; 36(2):129-35. PubMed ID: 19217524
[TBL] [Abstract][Full Text] [Related]
6. Comparative Evaluation of Using NOTA and DOTA Derivatives as Bifunctional Chelating Agents in the Preparation of
Guleria M; Das T; Amirdhanayagam J; Sarma HD; Dash A
Cancer Biother Radiopharm; 2018 Feb; 33(1):8-16. PubMed ID: 29373046
[TBL] [Abstract][Full Text] [Related]
7. Development of novel radiogallium-labeled bone imaging agents using oligo-aspartic acid peptides as carriers.
Ogawa K; Ishizaki A; Takai K; Kitamura Y; Kiwada T; Shiba K; Odani A
PLoS One; 2013; 8(12):e84335. PubMed ID: 24391942
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of a novel 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imaging.
Suzuki K; Satake M; Suwada J; Oshikiri S; Ashino H; Dozono H; Hino A; Kasahara H; Minamizawa T
Nucl Med Biol; 2011 Oct; 38(7):1011-8. PubMed ID: 21982572
[TBL] [Abstract][Full Text] [Related]
9. In vivo comparison of DOTA based 68Ga-labelled bisphosphonates for bone imaging in non-tumour models.
Meckel M; Fellner M; Thieme N; Bergmann R; Kubicek V; Rösch F
Nucl Med Biol; 2013 Aug; 40(6):823-30. PubMed ID: 23915801
[TBL] [Abstract][Full Text] [Related]
10. Preparation, quality control and biodistribution assessment of ¹⁵³Sm-BPAMD as a novel agent for bone pain palliation therapy.
Rabie A; Enayati R; Yousefnia H; Jalilian AR; Shamsaei M; Zolghadri S; Bahrami-Samani A; Hosntalab M
Ann Nucl Med; 2015 Dec; 29(10):870-6. PubMed ID: 26260999
[TBL] [Abstract][Full Text] [Related]
11. Samarium-153-(4-[((bis (phosphonomethyl)) carbamoyl) methyl]-7,10-bis (carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl) acetic acid: A novel agent for bone pain palliation therapy.
Yousefnia H; Enayati R; Hosntalab M; Zolghadri S; Bahrami-Samani A
J Cancer Res Ther; 2016; 12(3):1117-1123. PubMed ID: 28054521
[TBL] [Abstract][Full Text] [Related]
12. Design of Ga-DOTA-based bifunctional radiopharmaceuticals: two functional moieties can be conjugated to radiogallium-DOTA without reducing the complex stability.
Mukai T; Suwada J; Sano K; Okada M; Yamamoto F; Maeda M
Bioorg Med Chem; 2009 Jul; 17(13):4285-9. PubMed ID: 19481944
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of bifunctional chelates for the development of gallium-based radiopharmaceuticals.
Ferreira CL; Lamsa E; Woods M; Duan Y; Fernando P; Bensimon C; Kordos M; Guenther K; Jurek P; Kiefer GE
Bioconjug Chem; 2010 Mar; 21(3):531-6. PubMed ID: 20175523
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of a novel 68Ga-labeled DOTA-benzamide derivative for malignant melanoma imaging.
Kim HJ; Kim DY; Park JH; Yang SD; Hur MG; Min JJ; Yu KH
Bioorg Med Chem Lett; 2012 Aug; 22(16):5288-92. PubMed ID: 22796183
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Evaluation of Ga-68-Labeled Rhein for Early Assessment of Treatment-Induced Tumor Necrosis.
Zhang A; Wu T; Bian L; Li P; Liu Q; Zhang D; Jin Q; Zhang J; Huang G; Song S
Mol Imaging Biol; 2020 Jun; 22(3):515-525. PubMed ID: 31250330
[TBL] [Abstract][Full Text] [Related]
16. (68)Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter.
Fellner M; Biesalski B; Bausbacher N; Kubícek V; Hermann P; Rösch F; Thews O
Nucl Med Biol; 2012 Oct; 39(7):993-9. PubMed ID: 22633217
[TBL] [Abstract][Full Text] [Related]
17. Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation.
Abbasi IA
Nucl Med Biol; 2011 Apr; 38(3):417-25. PubMed ID: 21492790
[TBL] [Abstract][Full Text] [Related]
18. H(2)azapa: a versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)Lu.
Bailey GA; Price EW; Zeglis BM; Ferreira CL; Boros E; Lacasse MJ; Patrick BO; Lewis JS; Adam MJ; Orvig C
Inorg Chem; 2012 Nov; 51(22):12575-89. PubMed ID: 23106422
[TBL] [Abstract][Full Text] [Related]
19. A radiogallium-DOTA-based bivalent peptidic ligand targeting a chemokine receptor, CXCR4, for tumor imaging.
Sano K; Masuda R; Hisada H; Oishi S; Shimokawa K; Ono M; Fujii N; Saji H; Mukai T
Bioorg Med Chem Lett; 2014 Mar; 24(5):1386-8. PubMed ID: 24491461
[TBL] [Abstract][Full Text] [Related]
20. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting.
Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM
Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
